{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:57:22Z","timestamp":1792508242208,"version":"4.5.0"},"reference-count":29,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2024,10,2]]},"DOI":"10.2967\/jnumed.124.268277","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:25:27Z","timestamp":1730305527000},"page":"jnumed.124.268277","source":"Crossref","is-referenced-by-count":7,"title":["Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [<sup>177<\/sup>Lu]Lu-PSMA-617"],"prefix":"10.2967","author":[{"given":"Miguel","family":"Muniz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob J.","family":"Orme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina M.","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana R.","family":"Rosenow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack R.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Kase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irbaz B.","family":"Riaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokce","family":"Belge Bilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Tuba","family":"Kendi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praful","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene D.","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel S.","family":"Childs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,10,30]]},"reference":[{"key":"2024103009251144000_jnumed.124.268277v1.1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-021-00261-6","article-title":"Liver metastases","volume":"7","author":"Tsilimigras","year":"2021","journal-title":"Nat Rev Dis Primers."},{"key":"2024103009251144000_jnumed.124.268277v1.2","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.3390\/cancers14246189","article-title":"Liver microenvironment response to prostate cancer metastasis and hormonal therapy","volume":"14","author":"Buxton","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2024103009251144000_jnumed.124.268277v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2013.41"},{"key":"2024103009251144000_jnumed.124.268277v1.4","doi-asserted-by":"crossref","first-page":"1652\u20131659","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol."},{"key":"2024103009251144000_jnumed.124.268277v1.5","doi-asserted-by":"crossref","first-page":"671\u2013677","DOI":"10.1200\/JCO.2013.52.3696","article-title":"Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer","volume":"32","author":"Halabi","year":"2014","journal-title":"J Clin Oncol."},{"key":"2024103009251144000_jnumed.124.268277v1.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2017.02.007"},{"key":"2024103009251144000_jnumed.124.268277v1.7","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30336"},{"key":"2024103009251144000_jnumed.124.268277v1.8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcancer.2020.07.004","article-title":"Prostate cancer liver metastasis: dormancy and resistance to therapy","volume":"71","author":"Ma","year":"2021","journal-title":"Semin Cancer Biol."},{"key":"2024103009251144000_jnumed.124.268277v1.9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/jjco\/hyad128","article-title":"Baseline characteristics may impact treatment duration of cabazitaxel in patients with mCRPC: a subanalysis of data from a post-marketing surveillance","volume":"54","author":"Matsubara","year":"2024","journal-title":"Jpn J Clin Oncol."},{"key":"2024103009251144000_jnumed.124.268277v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.09.024"},{"key":"2024103009251144000_jnumed.124.268277v1.11","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clgc.2023.08.004","article-title":"Overall survival of metastatic prostate cancer patients according to location of visceral metastatic sites","volume":"22","author":"Tappero","year":"2024","journal-title":"Clin Genitourin Cancer."},{"key":"2024103009251144000_jnumed.124.268277v1.12","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40169-019-0247-4","article-title":"Sites of synchronous distant metastases and prognosis in prostate cancer patients with bone metastases at initial diagnosis: a population-based study of 16,643 patients","volume":"8","author":"Zhao","year":"2019","journal-title":"Clin Transl Med."},{"key":"2024103009251144000_jnumed.124.268277v1.13","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2024103009251144000_jnumed.124.268277v1.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107322"},{"key":"2024103009251144000_jnumed.124.268277v1.15","doi-asserted-by":"crossref","first-page":"e2300634","DOI":"10.1200\/PO.23.00634","article-title":"Genomic correlates of prostate-specific membrane antigen expression and response to 177Lu-PSMA-617: a retrospective multicenter cohort study","volume":"8","author":"Raychaudhuri","year":"2024","journal-title":"JCO Precis Oncol."},{"key":"2024103009251144000_jnumed.124.268277v1.16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol."},{"key":"2024103009251144000_jnumed.124.268277v1.17","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0564"},{"key":"2024103009251144000_jnumed.124.268277v1.18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30336"},{"key":"2024103009251144000_jnumed.124.268277v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30408-5"},{"key":"2024103009251144000_jnumed.124.268277v1.20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00259-020-04828-5","article-title":"Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy","volume":"48","author":"Khreish","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024103009251144000_jnumed.124.268277v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00274-6"},{"key":"2024103009251144000_jnumed.124.268277v1.22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.2024.42.4_suppl.212","article-title":"Evaluation of ctDNA in patients with mCRPC with liver metastases [abstract]","volume":"42","author":"Huang","year":"2024","journal-title":"J Clin Oncol."},{"key":"2024103009251144000_jnumed.124.268277v1.23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jvir.2022.05.023","article-title":"Yttrium-90 radioembolization for liver-dominant metastatic prostate cancer: a case series","volume":"33","author":"Bibok","year":"2022","journal-title":"J Vasc Interv Radiol."},{"key":"2024103009251144000_jnumed.124.268277v1.24","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","article-title":"Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial","volume":"24","author":"Aggarwal","year":"2023","journal-title":"Lancet Oncol."},{"key":"2024103009251144000_jnumed.124.268277v1.25","doi-asserted-by":"crossref","first-page":"5005","DOI":"10.1200\/JCO.2023.41.16_suppl.5005","article-title":"LuPARP: phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC) [abstract]","volume":"41","author":"Sandhu","year":"2023","journal-title":"J Clin Oncol."},{"key":"2024103009251144000_jnumed.124.268277v1.26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","article-title":"Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study","volume":"25","author":"Sathekge","year":"2024","journal-title":"Lancet Oncol."},{"key":"2024103009251144000_jnumed.124.268277v1.27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.semnuclmed.2024.03.004","article-title":"Advances in PSMA alpha theragnostics","volume":"54","author":"Vorster","year":"2024","journal-title":"Semin Nucl Med."},{"key":"2024103009251144000_jnumed.124.268277v1.28","first-page":"P1","article-title":"Excellent therapeutic outcome of PSMA-targeted alpha therapy in an end-stage prostate cancer patient with visceral metastasis before exposure to beta therapy [abstract]","volume":"64","author":"Gupta","year":"2023","journal-title":"J Nucl Med."},{"key":"2024103009251144000_jnumed.124.268277v1.29","doi-asserted-by":"crossref","first-page":"5055","DOI":"10.1200\/JCO.2024.42.16_suppl.5055","article-title":"Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [177Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603) [abstract]","volume":"42","author":"Kwan","year":"2024","journal-title":"J Clin Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.124.268277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:25:33Z","timestamp":1730305533000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.124.268277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,30]]},"references-count":29,"alternative-id":["10.2967\/jnumed.124.268277"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.124.268277","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,30]]}}}